Current staging methods are lack of precision in predicting prognosis of early-stage lung adenocarcinomas.
OBJECTIVE:
We aimed to develop a gene expression signature to identify high- and low-risk groups of patients.
METHODS:
We used the Bayesian Model Averaging algorithm to analyze the DNA microarray data from 442 lung adenocarcinoma patients from three independent cohorts, one of which was used for training.
RESULTS:
The patients were assigned to either high- or low-risk groups based on the calculated risk scores based on the identified 25-gene signature. The prognostic power was evaluated using Kaplan-Meier analysis and the log-rank test. The testing sets were divided into two distinct groups with log-rank test p-values of 0.00601 and 0.0274 respectively.
CONCLUSIONS:
Our results show that the prognostic models could successfully predict patients' outcome and serve as biomarkers for early-stage lung adenocarcinoma overall survival analysis.
JemalA., SiegelR., XuJ. and WardE., Cancer statistics, 2010, CA Cancer J Clin60 (2010), 277-300.
2.
HowingtonJ.A., BlumM.G., ChangA.C., BalekianA.A. and MurthyS.C., Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest143 (2013), e278S-313S.
3.
SuzukiK., KachalaS.S., KadotaK., ShenR., MoQ., BeerD.G., RuschV.W., TravisW.D. and AdusumilliP.S., Prognostic immune markers in non-small cell lung cancer, Clin Cancer Res17 (2011), 5247-56.
4.
BhattacharjeeA., RichardsW.G., StauntonJ., LiC., MontiS., VasaP., LaddC., BeheshtiJ., BuenoR., GilletteM., LodaM., WeberG., MarkE.J., LanderE.S., WongW., JohnsonB.E., GolubT.R., SugarbakerD.J. and MeyersonM., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses, Proc Natl Acad Sci U S A98 (2001), 13790-5.
LuY., LemonW., LiuP.Y., YiY., MorrisonC., YangP., SunZ., SzokeJ., GeraldW.L., WatsonM., GovindanR. and YouM., A gene expression signature predicts survival of patients with stage I non-small cell lung cancer, PLoS Med3 (2006), e467.
7.
ChenH.Y., YuS.L., ChenC.H., ChangG.C., ChenC.Y., YuanA., ChengC.L., WangC.H., TerngH.J., KaoS.F., ChanW.K., LiH.N., LiuC.C., SinghS., ChenW.J., ChenJ.J. and YangP.C., A five-gene signature and clinical outcome in non-small-cell lung cancer, N Engl J Med356 (2007), 11-20.
8.
GuoN.L., WanY.W., TosunK., LinH., MsiskaZ., FlynnD.C., RemickS.C., VallyathanV., DowlatiA., ShiX., CastranovaV., BeerD.G. and QianY., Confirmation of gene expression-based prediction of survival in non-small cell lung cancer, Clin Cancer Res14 (2008), 8213-20.
9.
SunZ., WigleD.A. and YangP., Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival, J Clin Oncol26 (2008), 877-83.
10.
RoepmanP., JassemJ., SmitE.F., MuleyT., NiklinskiJ., van de VeldeT., WitteveenA.T., RzymanW., FlooreA., BurgersS., GiacconeG., MeisterM., DienemannH., SkrzypskiM., KozlowskiM., MooiW.J. and van ZandwijkN., An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer, Clin Cancer Res15 (2009), 284-90.
11.
PerumalD., SinghS., YoderS.J., BloomG.C. and ChellappanS.P., A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC, PLoS One7 (2012), e43589.
12.
BotlingJ., EdlundK., LohrM., HellwigB., HolmbergL., LambeM., BerglundA., EkmanS., BergqvistM., PontenF., KonigA., FernandesO., KarlssonM., HeleniusG., KarlssonC., RahnenfuhrerJ., HengstlerJ.G. and MickeP., Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation, Clin Cancer Res19 (2013), 194-204.
13.
SubramanianJ. and SimonR., Gene expression-based prognostic signatures in lung cancer: ready for clinical use?, J Natl Cancer Inst102 (2010), 464-74.
14.
ZhangH.H. and LuW., Adaptive Lasso for Cox's proportional hazards model, Biometrika94 (2007), 691-703.
15.
NguyenD.V. and RockeD.M., Partial least squares proportional hazard regression for application to DNA microarray survival data, Bioinformatics18 (2002), 1625-32.
16.
LiH. and GuiJ., Partial Cox regression analysis for high-dimensional microarray gene expression data, Bioinformatics 20 Suppl1 (2004), i208-15.
17.
AnnestA., BumgarnerR.E., RafteryA.E. and YeungK.Y., Iterative Bayesian Model Averaging: a method for the application of survival analysis to high-dimensional microarray data, BMC Bioinformatics10 (2009), 72.
18.
HoetingJ.A., MadiganD., RafteryA.E. and VolinskyC.T., Bayesian model averaging: a tutorial (with comments by ClydeM., DraperD. and GeorgeE.I., and a rejoinder by the authors, (1999), 382-417.
19.
YeungK.Y., BumgarnerR.E. and RafteryA.E., Bayesian model averaging: development of an improved multi-class, gene selection and classification tool for microarray data, Bioinformatics21 (2005), 2394-402.
20.
OkayamaH., KohnoT., IshiiY., ShimadaY., ShiraishiK., IwakawaR., FurutaK., TsutaK., ShibataT., YamamotoS., WatanabeS., SakamotoH., KumamotoK., TakenoshitaS., GotohN., MizunoH., SaraiA., KawanoS., YamaguchiR., MiyanoS. and YokotaJ., Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas, Cancer Res72 (2012), 100-11.
DerS.D., SykesJ., PintilieM., ZhuC.Q., StrumpfD., LiuN., JurisicaI., ShepherdF.A. and TsaoM.S., Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients, J Thorac Oncol9 (2014), 59-64.
23.
RafteryA.E., Bayesian model selection in social research, Sociological methodology25 (1995), 111-164.
24.
VolinskyC.T., MadiganD., RafteryA.E. and KronmalR.A., Bayesian model averaging in proportional hazard models: assessing the risk of a stroke, Journal of the Royal Statistical Society: Series C (Applied Statistics)46 (1997), 433-448.
25.
FurnivalG.M. and WilsonR.W., Regressions by Leaps and Bounds, Technometrics16 (1974), 499-511.
26.
CoxD.R., Regression models and life-tables, Journal of the Royal Statistical Society. Series B (Methodological) (1972), 187-220.
27.
KaplanE.L. and MeierP., Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association53 (1958), 457-481.
28.
ChenD.Q., PanB.Z., HuangJ.Y., ZhangK., CuiS.Y., DeW., WangR. and ChenL.B., HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells, Oncotarget5 (2014), 3333-49.
29.
MithraprabhuS., KalffA., ChowA., KhongT. and SpencerA., Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma, Epigenetics9 (2014), 1511-20.
30.
BaoZ.S., LiM.Y., WangJ.Y., ZhangC.B., WangH.J., YanW., LiuY.W., ZhangW., ChenL. and JiangT., Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling, CNS Neurosci Ther20 (2014), 112-8.
31.
MorenoD.A., ScrideliC.A., CortezM.A., de Paula QueirozR., ValeraE.T., da Silva SilveiraV., YunesJ.A., BrandaliseS.R. and ToneL.G., Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia, Br J Haematol150 (2010), 665-73.
32.
GruhnB., NaumannT., GrunerD., WaltherM., WittigS., BeckerS., BeckJ.F. and SonnemannJ., The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia, Leuk Res37 (2013), 1200-7.
33.
NetaG., BrennerA.V., SturgisE.M., PfeifferR.M., HutchinsonA.A., Aschebrook-KilfoyB., YeagerM., XuL., WheelerW., AbendM., RonE., TuckerM.A., ChanockS.J. and SigurdsonA.J., Common genetic variants related to genomic integrity and risk of papillary thyroid cancer, Carcinogenesis32 (2011), 1231-7.
34.
KamalakaranS., VaradanV., Giercksky RussnesH.E., LevyD., KendallJ., JanevskiA., RiggsM., BanerjeeN., SynnestvedtM., SchlichtingE., KaresenR., Shama PrasadaK., RottiH., RaoR., RaoL., Eric TangM.H., SatyamoorthyK., LucitoR., WiglerM., DimitrovaN., NaumeB., Borresen-DaleA.L. and HicksJ.B., DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables, Mol Oncol5 (2011), 77-92.
35.
ZhangJ., YangY., YangT., LiuY., LiA., FuS., WuM., PanZ. and ZhouW., microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity, Br J Cancer103 (2010), 1215-20.
36.
HoffmannK., FirthM.J., BeesleyA.H., FreitasJ.R., FordJ., SenanayakeS., de KlerkN.H., BakerD.L. and KeesU.R., Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index, Br J Haematol140 (2008), 656-64.
37.
OnkenM.D., EhlersJ.P., WorleyL.A., MakitaJ., YokotaY. and HarbourJ.W., Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas, Cancer Res66 (2006), 4602-9.
